BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33488516)

  • 21. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should Total Thyroidectomy Be Recommended for Patients with Familial Non-medullary Thyroid Cancer?
    Kim YS; Seo M; Park SH; Ju SY; Kim ES
    World J Surg; 2020 Sep; 44(9):3022-3027. PubMed ID: 32556933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
    de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
    Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of
    Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
    Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer.
    Orois A; Badenas C; Reverter JL; López V; Potrony M; Mora M; Halperin I; Oriola J
    Horm Cancer; 2020 Apr; 11(2):111-116. PubMed ID: 32172474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
    Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
    J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
    Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
    Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of
    Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
    Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
    [No Abstract]   [Full Text] [Related]  

  • 29. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
    Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
    Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
    Gara SK; Jia L; Merino MJ; Agarwal SK; Zhang L; Cam M; Patel D; Kebebew E
    N Engl J Med; 2015 Jul; 373(5):448-55. PubMed ID: 26222560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.
    Diquigiovanni C; Bergamini C; Evangelisti C; Isidori F; Vettori A; Tiso N; Argenton F; Costanzini A; Iommarini L; Anbunathan H; Pagotto U; Repaci A; Babbi G; Casadio R; Lenaz G; Rhoden KJ; Porcelli AM; Fato R; Bowcock A; Seri M; Romeo G; Bonora E
    Int J Cancer; 2018 Oct; 143(7):1706-1719. PubMed ID: 29672841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
    Hińcza K; Kowalik A; Kowalska A
    Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
    Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
    Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
    Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
    J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
    Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germ-line mutations in
    Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
    Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial non-medullary thyroid cancer: a matched-case control study.
    Maxwell EL; Hall FT; Freeman JL
    Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
    Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
    Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.